SNAC2 : A randomised phase III study to determine in women with early breast cancer whether sentinel node based management increases the risk of loco-regional recurrence and in particular, axillary recurrence, compared with axillary clearance in any subgroup of women.

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Surgical<br/>TrialTypeSurgical
Trial

ThreePhase Three

18-75Age 18-75

Breast<br/>CancersCancer LocationBreast
Cancers

Surgical | BreastBreast

Trial Overview Read MoreRead more

This phase III trial is assessing the effect of sentinal node based management on risk of recurrence in patients with early stage breast cancer.
 

This trial is treating patients with breast cancer.

This is a surgical trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A randomised phase III study to determine in women with early breast cancer whether sentinel node based management increases the risk of loco-regional recurrence and in particular, axillary recurrence, compared with axillary clearance in any subgroup of women.

Other Non-Commercial Sponsor

National Health & Medical Research Council (NHMRC)

Summary

SNAC-2 is a national trial comparing two operations for detecting cancer cells in the lymph nodes of women with early breast cancer. The two operations are: 1) axillary clearance and 2) sentinel node biopsy.

The standard of treatment for early stage breast cancer is axillary clearance which is the removal of most of the lymph nodes under the armpit (axilla). The new treatment is sentinel node biopsy where only the first few lymph nodes most closely related to the cancer are removed.

We know that removing only the sentinel nodes may cause fewer side effects than doing an axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next